Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Definitive Healthcare Corp. Chief Executive Officer Clay Brian Ritchey received a direct award of 2,626,263 restricted stock units (RSUs) on October 23, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. The reported direct position after the award was 2,626,263 RSUs. Twenty-five percent vest on September 8, 2027, followed by vesting of 6.25% every three months over the subsequent three years, subject to continued service through each vesting date.
Definitive Healthcare Corp. (DH) Chief Financial Officer Casey Heller reported the withholding of 12,542 shares of Class A Common Stock on October 1, 2026, to satisfy tax withholding obligations tied to vesting and settlement of previously reported RSUs. The reported price was $0.9361 per share; Casey Heller reported direct holdings of 1,785,960 shares following the transaction.
Definitive Healthcare Corp. Chief Legal Officer Jonathan Paris had 7,729 shares of Class A Common Stock withheld by the issuer on October 1, 2026, to satisfy tax-withholding obligations connected with vesting and settlement of previously reported RSUs. The reported price was $0.9361 per share. Afterward, he directly held 864,534 shares.
Definitive Healthcare Corp. (DH) reports that Advent International, L.P. entered a confidentiality agreement with it on September 29, 2026, to consider, evaluate and negotiate a transaction. Advent International, L.P. and Advent International GP, LLC each report beneficial ownership of 62,493,676 shares, or 58.54%. Advent International GPE IX Limited Partnership reports 16,955,510 shares (15.88%), and Advent International GPE IX-H Limited Partnership reports 5,428,915 shares (5.09%). The percentages use 106,744,713 shares outstanding as of August 6, 2026. The reporting persons state they had not effected transactions in Common Stock since the original statement.
The agreement includes 12-month non-solicitation and standstill provisions, subject to exceptions and, for certain actions, the issuer’s prior written consent. It generally limits disclosure and use of confidential information, with stated exceptions. Advent International, L.P. intends to continue engaging with the Special Committee and third parties, including Mr. Krantz, regarding a transaction.
Definitive Healthcare Corp. (DH) filed an initial ownership report for Ritchey Clay Brian, who serves as both Chief Executive Officer and director. The filing indicates beneficial ownership of 5,000 shares of Class A Common Stock, held indirectly via an IRA, with no specific buy or sell transactions reported.
Definitive Healthcare Corp. (DH) reports that the holders under its existing Tax Receivable Agreement (TRA) have agreed among themselves to an irrevocable waiver of any right to receive an Early Termination Payment in connection with a Qualifying Change of Control, defined as a Change of Control whose definitive merger agreement is executed on or before December 31, 2026.
For any such Qualifying Change of Control that is consummated, the TRA will terminate in accordance with its terms, and the TRA parties will take actions reasonably necessary to effect that termination. All other rights under the TRA, including rights to tax benefit payments for taxable years ending prior to, with, or including the consummation of a Qualifying Change of Control, remain unchanged. Definitive Healthcare is not a party to this waiver; it is being described for informational purposes under Regulation FD.
Definitive Healthcare Corp. (DH) reported that Chief Financial Officer Casey Heller had 41,093 shares of Class A common stock withheld by the issuer on September 1, 2026 to satisfy tax withholding obligations related to the vesting and settlement of previously reported RSUs, at a reference price of $0.9023 per share. Following this tax-withholding disposition, Heller directly holds 1,798,502 shares of Class A common stock, and no Rule 10b5-1 trading plan is reported.
Definitive Healthcare Corp. (DH) disclosed that a Special Committee of its board has received a non-binding indication of interest from Advent International, on behalf of certain managed funds, to take the company private. Advent proposes to acquire all outstanding shares of Class A common stock and Definitive OpCo Units that are not already owned by Advent or founder and Executive Chairman Jason Krantz for an all-cash price of $1.02 per share of Class A common stock and an equivalent amount per Definitive OpCo Unit.
The Special Committee, composed entirely of disinterested and independent directors, will review the proposal with independent legal and financial advisors and evaluate potential alternatives. No decisions have been made, no stockholder action is required at this time, and there is no assurance that any transaction or other strategic outcome will be approved or completed.
Definitive Healthcare Corp. (DH) is the subject of a new Schedule 13D filed by Executive Chairman Jason Ronald Krantz, who reports beneficial ownership of 22,497,978 shares of Class A Common Stock, representing 17.6% of the class, calculated against 106,744,713 shares outstanding as of August 10, 2026.
The filing is prompted by a preliminary, non-binding all-cash acquisition proposal submitted on September 1, 2026 by funds managed by Advent International, L.P. to acquire all outstanding Class A shares and LLC Units not already owned by Advent funds and Krantz at $1.02 per share (and an equivalent amount per LLC Unit. The proposal is premised on Krantz rolling over all of his Class A shares and LLC Units into equity of the surviving company and is subject to negotiation of definitive agreements, approval by a Special Committee of the board and regulatory approvals. Based on Advent’s separate filing, its funds beneficially own about 58.54% of DH; together with Krantz they may be deemed a “group” holding 66.36% of the Class A shares, though Krantz disclaims group status. The filing emphasizes there is no assurance any definitive agreement will be reached or that the transaction will be completed.
Definitive Healthcare Corp. (DH) announced that its Board appointed Clay Ritchey as Chief Executive Officer and director, effective September 8, 2026, under an employment agreement dated August 28, 2026. Ritchey brings more than 25 years of leadership experience at healthcare-focused technology and data companies, including Verato and Evariant.
Under his agreement, Ritchey will receive a $500,000 annual base salary, a target annual bonus equal to 87.5% of base salary, and eligibility for annual equity awards with an initial target of at least $2,000,000. He will also receive a one-time New Hire Equity Incentive valued at $4,000,000, split between time-based and performance-based restricted stock units.
The company disclosed severance protections for certain terminations, including salary continuation, bonus payments, and equity vesting benefits, with enhanced terms if a qualifying termination occurs in connection with a Change in Control. Definitive Healthcare also reported that prior CEO Kevin Coop stepped down as CEO and director effective August 31, 2026, and that his departure was not due to any disagreement regarding company operations, policies, or practices.